

file

FORM PTO-1449 (Modified)		Attorney Docket No.: 20093A-002100US		Application No.: 09/301,380	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Gerald P. Murphy, <i>et al.</i>			
		Filing Date: June 15, 2001		Group: 1635	
Reference Designation		U.S. PATENT DOCUMENTS			Page 1 of 1
Examiner Initial	Document	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Sub-class
					Translation (Yes/No)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
<u>mmS</u> AA	Schwab, G. <i>et al.</i> , <i>An Approach for New Anticancer Drugs: Oncogene-Targeted Antisense DNA</i> , <u>Annals of Oncology</u> 5:55-58, 1994.				
<u>mmS</u> AB	Matveeva, O. <i>et al.</i> , <i>A Rapid In Vitro Method For Obtaining RNA Accessibility Patterns For Complementary DNA Probes: Correlation With An Intracellular Pattern and Known RNA Structures</i> , <u>Nucleic Acids Res.</u> 25:5010-6, 1997.				
<u>mmS</u> AC	Flanagan, Michael W., <i>Antisense Comes of Age</i> , <u>Cancer and Metastasis Reviews</u> 17:169-176, 1998.				
<u>mmS</u> AD	Ho, Siew Peng <i>et al.</i> , <i>Antisense Oligonucleotides for Target Validation in the CNS</i> , <u>Current Opinion in Molecular Therapeutics</u> 1:336-343, 1999.				
<u>mmS</u> AE	Holmlund, Jon T <i>et al.</i> , <i>Toward Antisense Oligonucleotide Therapy for Cancer: ISIS Compounds in Clinical Development</i> , <u>Current Opinion in Molecular Therapeutics</u> 1:372-385, 1999.				
<u> </u> AF					
<u> </u> AG					
<u> </u> AH					
<u> </u> AI					
<u> </u> AJ					
<u> </u> AK					
<u> </u> AL					
<u> </u> AM					
<u> </u> AN					
EXAMINER		DATE CONSIDERED			
mm Schmidt		8/25/02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
5012889v1